MACK

Merrimack Pharmaceuticals, Inc.

12.82 USD

Last updated Dec 8, 06:05 UTC

Yesterday HIGH

$13.05

Yesterday LOW

$12.62

52w HIGH

$13.15

52w LOW

$10.1

EPS

-0.02

PE

-641.00

Next Earnings

Mar 7, 2024

Overview News Insider Transactions Government Trades

Merrimack Pharmaceuticals, Inc. stock is up 4.57% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 11 December’s closed higher than November.

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Cambridge, United States Of America

Website

merrimack.com

Vandana Singh

Wed Nov 9, 2022

Why Merrimack Shares Are Surging Over 200% Today?
Benzinga Insights

Wed Nov 9, 2022

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Merrimack Pharmaceuticals (NASDAQ:MACK) shares rose 180.0% to $11.2 during Wednesday's pre-market session. The company's market cap stands at $150.1 million. As per the news, the Q3 earnings report came out 4 days ago.
Charles Gross

Wed Nov 9, 2022

Shares of Merrimack Pharmaceuticals Rise 100% Preamarket Following Ipsen Report that Onivyde Met Primary and Key Secondary Endpoint; Merrimack is Eligible for Up to $450M Milestone Payment for the Pancreatic Cancer Treatment
Charles Gross

Wed Nov 9, 2022

Ipsen Announced Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma; Trial Met its Primary Endpoint and Key Secondary Endpoint

Ipsen (Euronext: IPN; ADR: IPSEY) announced the Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) met its primary endpoint demonstrating clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metasta
Benzinga Newsdesk

Thu Nov 3, 2022

UPDATE: Merrimack Pharmaceuticals Q3 EPS $(0.03) Up From $(0.04) YoY

Merrimack Pharmaceuticals (NASDAQ:MACK) reported quarterly losses of $(0.03) per share. This is a 25 percent increase over losses of $(0.04) per share from the same period last year.
Benzinga Newsdesk

Thu Nov 3, 2022

Merrimack Pharmaceuticals Q3 EPS $(0.03) Up From $(0.04) YoY

Merrimack Pharmaceuticals (NASDAQ:MACK) reported quarterly earnings of $(0.03) per share. This is a 175 percent increase over losses of $(0.04) per share from the same period last year.
Lisa Levin

Tue Oct 18, 2022

Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday

Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case.
Benzinga Insights

Mon Oct 10, 2022

Stocks That Hit 52-Week Lows On Monday

During Monday's trading, 528 companies set new 52-week lows.
Benzinga Insights

Fri Oct 7, 2022

Stocks That Hit 52-Week Lows On Friday

On Friday, 404 stocks made new 52-week lows.
Benzinga Insights

Wed Oct 5, 2022

Stocks That Hit 52-Week Lows On Wednesday

Wednesday saw 127 companies set new 52-week lows.

Andersen Eric, Director

Fri Nov 17, 2023

MACK Recent Insider Trades and Stock Chart

300 shares bought
Andersen Eric, Director

Tue Nov 14, 2023

MACK Recent Insider Trades and Stock Chart

50,170 shares bought
Andersen Eric, Director

Wed Nov 8, 2023

MACK Recent Insider Trades and Stock Chart

13,823 shares bought
Andersen Eric, Director

Thu Nov 9, 2023

MACK Recent Insider Trades and Stock Chart

9,975 shares bought